Replies to post #117917 on Innovation Pharmaceuticals Inc (IPIX)

[TOB]

I disagree.

If he had partial or complete response we would have known by now given Leo had to PR something to stop the bleeding from the SA hack job. His "update" on trial progress would have most certainly included that. -iclight

CTIX has been very cautious in not releasing early data points from the ongoing Kevetrin Phase 1 clinical trial. Certainly not on a case by case basis. This despite the trial being open-label, not blinded.

The information about the ovarian cancer was partly to elaborate on why they had decided to successfully apply for Orphan Drug Status and focus a Phase 2 trial on Ovarian Cancer. They also used 3 and 6 month imaging.

The initial patient in the 11th cohort was not ovarian cancer, if the next two are ovarian cancer and have even completed their dosing cycle, it is unlikely they have completed a 3 month period post dosing.

The patient receiving Kevetrin for 11 months was PR'd because it is so intriguing. One doesn't expect a chemotherapeutic drug to be administered for 11 months, most are very toxic. They were responding to the flurry of emails inquiring about this case.

Personally, while I'm very happy to hear these clear indications of efficacy, my preference is for the company to wait until the trial is completed and release first the Top-Line and then the full clinical results. In our case, I expect to see the Kevetrin trial the subject of a peer reviewed journal article. Almost certainly in fact, as it was presented twice at ASCO by the principal investigator at Dana Farber.

It is not unusual for an emerging biotech to release preliminary data points from an open label clinical trial. Especially when the company and its science was unfairly and falsely maligned. I agree that may have encouraged what we did receive. But it can still be controversial and open the company up to criticism. Harvard's Dana Faber is Ivy League academia, and they especially frown on early release of data. They prefer scientific conferences such as ASCO and peer reviewed journals for data release. At set intervals of a trial in progress, and once the trial is complete and the data is fully analysed.